Emergent BioSolutions (EBS) Liabilities and Shareholders Equity (2010 - 2026)
Emergent BioSolutions (EBS) posted Liabilities and Shareholders Equity of $1.1 billion for Q2 2026, down 15.42% on a QoQ basis from $1.3 billion in Q1 2026, and down 21.19% year-over-year from $1.4 billion in Q2 2025.
Powered by 
Analysis
Emergent BioSolutions (EBS) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
Emergent BioSolutions has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $1.1 billion in Q2 2026.
- On a quarterly basis, Liabilities and Shareholders Equity fell 21.19% year-over-year to $1.1 billion in Q2 2026; TTM through Jun 2026 was $5.2 billion, a 8.65% decrease from a year earlier, with the FY2025 full-year figure at $1.3 billion, down 5.12% from the prior year.
- Liabilities and Shareholders Equity was $1.1 billion for Q2 2026 at Emergent BioSolutions, down from $1.3 billion in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $3.2 billion in Q4 2022, with the low at $1.1 billion in Q2 2026.
- Average Liabilities and Shareholders Equity over 5 years is $1.9 billion, with a median of $1.7 billion recorded in 2024.
- The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity climbed 7.05% in 2022, then sank 42.42% in 2023.
- Over 5 years, Liabilities and Shareholders Equity stood at $3.2 billion in 2022, then tumbled by 42.42% to $1.8 billion in 2023, then retreated by 23.78% to $1.4 billion in 2024, then fell by 5.12% to $1.3 billion in 2025, then fell by 15.3% to $1.1 billion in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $1.1 billion (Q2 2026), $1.3 billion (Q1 2026), and $1.3 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.47 Bn | 628.71 Bn | 17.26 Bn | 201.06 Bn |
| 2 | AbbVie | 467.46 Bn | 460.93 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 369.31 Bn | 362.22 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 269.03 Bn | 261.74 Bn | 11.24 Bn | 122.03 Bn |
| 5 | Pfizer | 158.11 Bn | 146.71 Bn | 10.94 Bn | 201.13 Bn |
| 6 | Bristol Myers Squibb | 127.96 Bn | 116.89 Bn | 9.25 Bn | 87.63 Bn |
| 7 | Sanofi | 51.83 Bn | 44.86 Bn | 10.79 Bn | 150.01 Bn |
| 8 | BeOne Medicines | 41.33 Bn | 36.23 Bn | 1.53 Bn | 9.18 Bn |
| 9 | Revolution Medicines | 41.30 Bn | 41.30 Bn | - | 4.32 Bn |
| 10 | Emergent BioSolutions | 335.50 Mn | 194.60 Mn | 137.20 Mn | 1.12 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.12 Bn |
| Mar 31, 2026 | 1.32 Bn |
| Dec 31, 2025 | 1.32 Bn |
| Sep 30, 2025 | 1.46 Bn |
| Jun 30, 2025 | 1.42 Bn |
| Mar 31, 2025 | 1.43 Bn |
| Dec 31, 2024 | 1.39 Bn |
| Sep 30, 2024 | 1.48 Bn |
| Jun 30, 2024 | 1.51 Bn |
| Mar 31, 2024 | 1.80 Bn |
| Dec 31, 2023 | 1.82 Bn |
| Sep 30, 2023 | 1.89 Bn |
| Jun 30, 2023 | 2.18 Bn |
| Mar 31, 2023 | 2.95 Bn |
| Dec 31, 2022 | 3.17 Bn |
| Sep 30, 2022 | 2.90 Bn |
| Jun 30, 2022 | 2.74 Bn |
| Mar 31, 2022 | 2.78 Bn |
| Dec 31, 2021 | 2.96 Bn |
| Sep 30, 2021 | 2.87 Bn |
API Access
Emergent BioSolutions Liabilities and Shareholders Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=EBS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "liabilities-and-shareholders-equity", "ticker": "EBS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=EBS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();